S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
NASDAQ:TECH

Bio-Techne - TECH Stock Forecast, Price & News

$80.67
-1.93 (-2.34%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$79.44
$82.80
50-Day Range
$70.50
$327.07
52-Week Range
$68.00
$130.74
Volume
683,031 shs
Average Volume
1.01 million shs
Market Capitalization
$12.66 billion
P/E Ratio
45.19
Dividend Yield
0.39%
Price Target
$114.06

Bio-Techne MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
39.1% Upside
$112.19 Price Target
Short Interest
Healthy
1.97% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.38mentions of Bio-Techne in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
23.91%
From $1.84 to $2.28 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.97 out of 5 stars

Medical Sector

20th out of 1,023 stocks

Biological Products, Except Diagnostic Industry

1st out of 170 stocks

TECH stock logo

About Bio-Techne (NASDAQ:TECH) Stock

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock News Headlines

Bio-Techne (NASDAQ:TECH) PT Lowered to $105.00
Bio-Techne (NASDAQ:TECH) Stock Rating Upgraded by StockNews.com
Should You Invest in Bio-Techne Corporation (TECH)?
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2023 RESULTS
BIO-TECHNE DECLARES CASH DIVIDEND AND STOCK DIVIDEND
Can Bio-Techne Corporation (TECH) Still Bounce Back?
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Company Calendar

Last Earnings
11/01/2021
Ex-Dividend for 11/28 Dividend
11/10/2022
Dividend Payable
11/28/2022
Today
12/06/2022
Next Earnings (Estimated)
2/07/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,000
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$112.19
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$90.00
Forecasted Upside/Downside
+41.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
5 Analysts

Profitability

Net Income
$272.05 million
Pretax Margin
30.22%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$2.41 per share
Book Value
$10.84 per share

Miscellaneous

Free Float
149,985,000
Market Cap
$12.66 billion
Optionable
Optionable
Beta
1.27

Social Links


Key Executives

  • Mr. Charles R. KummethMr. Charles R. Kummeth (Age 62)
    CEO, Pres & Director
    Comp: $5.07M
  • Mr. James T. HippelMr. James T. Hippel (Age 51)
    Exec. VP of Fin. & CFO
    Comp: $1.94M
  • Ms. Brenda S. Furlow J.D.Ms. Brenda S. Furlow J.D. (Age 64)
    Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer
    Comp: $1.46M
  • Mr. Kim  KeldermanMr. Kim Kelderman (Age 55)
    Pres of Diagnostics & Genomics
    Comp: $1.35M
  • Mr. William A. Geist (Age 52)
    Pres of Protein Sciences Segment
    Comp: $904.2k
  • David Clair
    Sr. Director of Investor Relations & Corp. Devel.
  • Mr. Gerry Andros
    VP of Sales and Marketing
  • Mr. Robert M. Gavin (Age 54)
    VP of Corp. Devel.
  • Ms. Brenda S. Everson
    Sr. VP & Chief HR Officer
  • Mr. Luca Cicchetti
    Managing Director













TECH Stock - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TECH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TECH, but not buy additional shares or sell existing shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price forecast for 2023?

5 Wall Street analysts have issued 12 month price objectives for Bio-Techne's shares. Their TECH share price forecasts range from $90.00 to $125.00. On average, they anticipate the company's stock price to reach $112.19 in the next twelve months. This suggests a possible upside of 39.1% from the stock's current price.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2022?

Bio-Techne's stock was trading at $129.3350 at the beginning of the year. Since then, TECH shares have decreased by 37.6% and is now trading at $80.67.
View the best growth stocks for 2022 here
.

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our TECH earnings forecast
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) issued its quarterly earnings data on Monday, November, 1st. The biotechnology company reported $0.46 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.03. The biotechnology company had revenue of $257.72 million for the quarter, compared to analysts' expectations of $254.37 million. Bio-Techne had a trailing twelve-month return on equity of 16.37% and a net margin of 26.13%. During the same quarter in the prior year, the business earned $0.29 EPS.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Tuesday, November 1st. Investors of record on Monday, November 14th will be given a dividend of $0.02 per share on Monday, November 28th. This represents a $0.08 dividend on an annualized basis and a yield of 0.10%. The ex-dividend date of this dividend is Thursday, November 10th.
Read our dividend analysis for TECH
.

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.39%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 17.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 14.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?

Bio-Techne shares split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly created shares were issued to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.44%), BlackRock Inc. (11.03%), State Street Corp (4.03%), Neuberger Berman Group LLC (2.64%), Ownership Capital B.V. (1.56%) and Marshall Wace LLP (1.48%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends
.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $80.67.

How much money does Bio-Techne make?

Bio-Techne (NASDAQ:TECH) has a market capitalization of $12.66 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $1.7850 on an earnings per share basis.

How many employees does Bio-Techne have?

The company employs 3,000 workers across the globe.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.

This page (NASDAQ:TECH) was last updated on 12/7/2022 by MarketBeat.com Staff